[1] Lee YH, Lee SG, Lee CJ, et al. Association between betatrophin/ANGPTL8 and non-alcoholic fatty liver disease: animal and human studies. Sci Rep, 2016, 6: 24013. [2] 刘悟,谭小青,阳军.前蛋白酶转化酶枯草溶菌素9:动脉粥样硬化性心血管疾病防治新靶点.临床心血管病杂志,2016,32(5):446-449. [3] 吴娜琼,李莎,郭远林,等.血浆PCSK9水平与冠状动脉狭窄程度的相关性研究.临床心血管病杂志,2016,32(3):260-264. [4] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018更新版). 中华肝脏病杂志,2018,34(5):641-649.[5] 林润杰,魏锦坤,周丽红.冠心病患者血清循环PCSK9水平与脂代谢和颈动脉粥样硬化的关系分析.中国循证心血管医学杂志,2019,11(6):684-687. [6] Lebeau PF,Byun JH, Platko K, et al. Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice. JHEP Rep,2019,1(6):418-429. [7] Santoso A,Y Yulianto,H Simarmata,Effect of PCSK9 E670G and R46L polymorphisms on major adverse cardio-cerebrovascular events in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Int J Angiol,2021,30(1):22-28. [8] 刘亚东.急性ST段抬高型心肌梗死合并多支血管病变病人血浆PCSK9水平对MACCE的预测价值.中西医结合心脑血管病杂志,2021,19(13):2233-2238. [9] Theocharidou E, Papademetriou M, Reklou A, et al. The role of PCSK9 in the pathogenesis of non-alcoholic fatty liver disease and the effect of PCSK9 inhibitors. Curr Pharm Des,2018,24(31):3654-3657. [10] 马利军,刘亚东,王丽萍.急性心肌梗死患者血清LDL-C及血浆PCSK9浓度对临床不良心脑血管事件的预测价值.岭南心血管病杂志,2021,27(3):248-253. [11] 谭静,高敬,张迎花,等.非阻塞性冠状动脉粥样硬化患者内皮功能不全的影响因素.中华老年多器官疾病杂志,2021,20(1):45-48. [12] 许嘉彬,谢凌鹏,王立波.PCSK9对动脉粥样硬化过程中细胞生物学功能的影响研究.华南国防医学杂志,2018,32(6):21-424. |